Invitae Akcija

Invitae EBITDA

Delisted·7. авг 2024.

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Invitae (NVTAQ) na dan 17. авг 2026. je 175,45 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -704,65 М USD — promjena od -124,90% (viši).

EBITDA

175,45 МUSD

YoY

-124,90%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Invitae je 2026 175,45 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Invitae je bio 2025 -704,65 М USD. Pad je time -124,90% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Invitae Анализа акција

Šta radi Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Invitae

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Invitae iznosi 175,45 М USD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Invitae se promijenio sa -704,65 М USD na 175,45 М USD, što predstavlja promjenu od -124,90%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Invitae od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Invitae istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Invitae

Sve ključne metrike — Invitae

Раст